Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27408827 | 0.80 | — | — | |
| SCHEMBL9122838 | 0.78 | LMNA (0.32) | TSHR | |
| SCHEMBL1618240 | 0.76 | CA2 (0.48) | SMN1; SMN2DHFRTSHRTDP1KDM4E | |
| SCHEMBL24178088 | 0.76 | ALDH1A1 (0.36) | CA2PKM | |
| SCHEMBL16519693 | 0.75 | DHFR (0.31) | SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL21125610 | 0.74 | CA12 (0.36) | KDM4ECA2 | |
| SCHEMBL19630966 | 0.74 | KMT2A (0.31) | — | |
| SCHEMBL1598836 | 0.74 | — | — | |
| SCHEMBL17286563 | 0.72 | ALDH1A1 (0.40) | SMN1; SMN2CA2 | |
| SCHEMBL1598837 | 0.72 | CA1 (0.30) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| CN-117623992-A | Lewis acid-promoted N-acyl sulfonamide direct transfer acylation method | 荆楚理工学院 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603101-A | Lewis acid-promoted non-hydrolytic deacylation method for N-acyl secondary sulfonamide | 荆楚理工学院 | 2024-02-27 | — | — | CN | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230278993-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2014047427-A2 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
| US-7754773-B2 | Composition and synthesis of new reagents for inhibition of HIV replication | UNIVERSITY OF MASSACHUSETTS (US) | 2010-07-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278993-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDCD1, CD274, PDCD1LG2 | SMN1; SMN2 3869/4885DHFR 1706/4885TSHR 2766/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | SMN1; SMN2 4483/4885DHFR 4738/4885TSHR 98/4885 |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | SMN1; SMN2 2273/4885DHFR 2976/4885TSHR 4640/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | SMN1; SMN2 4483/4885DHFR 4738/4885TSHR 98/4885 |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | SMN1; SMN2 843/4885DHFR 671/4885TSHR 1319/4885 |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, SLC10A2 | SMN1; SMN2 4664/4885DHFR 1016/4885TSHR 805/4885 |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | REV1, MAVS, ISG15 | SMN1; SMN2 4378/4885DHFR 153/4885TSHR 4711/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | SMN1; SMN2 4686/4885DHFR 1482/4885TSHR 429/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | SMN1; SMN2 4483/4885DHFR 4738/4885TSHR 98/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | SMN1; SMN2 843/4885DHFR 671/4885TSHR 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.